Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $6.7200 (15.96%) ($6.7200 - $6.7200) on Wed. Sep. 7, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.16% (three month average) | RSI | 46 | Latest Price | $6.7200(15.96%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.2% a day on average for past five trading days. | Weekly Trend | TGTX declines -2.1% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) IBUY(82%) SMH(76%) IGOV(72%) SPLV(69%) IPO(96%) | Factors Impacting TGTX price | TGTX will decline at least -3.58% in a week (0% probabilities). USO(-37%) OIH(-9%) EMHY(48%) TBT(-94%) UUP(-63%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.58% (StdDev 7.16%) | Hourly BBV | 0.4 () | Intraday Trend | 0% | | | |
|
Resistance Level | $7.18 | 5 Day Moving Average | $6.77(-0.74%) | 10 Day Moving Average | $6.89(-2.47%) | 20 Day Moving Average | $7.18(-6.41%) | To recent high | -20.2% | To recent low | 79.9% | Market Cap | $851m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |